Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
The worry is that India's cavalier approach to intellectual property may catch on in other parts of the developing world
'Mortality or hospitalisation has not increased in South Africa because of the new variant.' 'There is nothing to show so far that it is more infectious.' 'I am of the opinion that at the moment, there is no reason to panic.'
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
This week, global drugmakers Pfizer and BioNTech said their COVID-19 vaccine candidate is 95 per cent effective, including in adults over 65 years of age.
India battles big pharma over cough syrup abuse, reducing supplies
'Ideally, the efficacy data of all the trials should be there in the public domain, and as soon as possible.' 'It is difficult to understand the reason behind the authorisation.'
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Companies say they follow global standards in India as well
Biotech company denies all charges.
Less than three months after roaring into us market with generic for cholesterol-reducing Lipitor, Dept of Justice files for permanent injunction against Ranbaxy.
Addressing a press briefing, Union Health Secretary Rajesh Bhushan said healthcare workers and frontline workers need not register themselves as their database has been populated on to the Co-WIN vaccine delivery management system in a bulk manner.
'A third wave is possible, but we must try to restrict it to a low level by adopting all personal protection and public policy measures to prevent viral transmission, while speeding up vaccination.'
The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
As of Thursday, he said total deaths in America due to COVID-19 is over 527,000. That's more deaths than in World War I, World War II, the Vietnam War, and 9/11 combined, he said.
Mylan had sued the United States Food and Drugs Administration for providing the exclusive right to Ranbaxy, alleging the permission was given on the basis of 'falsified data'.
Severe price cuts help multinationals ramp up growth, gain market share.
Cambridge, Massachusetts-based Moderna's announcement comes just a week after Pfizer and Biontech said their COVID-19 vaccine candidate was found to be more than 90 per cent effective in preventing COVID-19 in participants.
The ministry has asked 44 pharmaceutical companies, including global drug majors such as Eli Lilly, Novartis, Pfizer, Bayer, Merck, Johnson & Johnson and Sanofi Aventis, to explain why they have not given the compensation, which is mandatory under the current drug laws.
In an effort to improve their balance sheets, many of the major multinationals have started to lay-off employees.
Snooping is one of the oldest peccadilloes of man, observes Ambassador M K Bhadrakumar.
The anti-depressant drug market in the US is primarily ruled by Effexor XR (Venlafaxine) of Wyeth (now owned by Pfizer).
AstraZeneca Plc and the University of Oxford are facing questions about their Covid-19 vaccine and whether regulators would quickly authorise its emergency use after the pharma company acknowledged an error in the vaccine dosage received by some participants and other irregularities and omissions, according to the New York Times.
''None of the existing vaccines have 100% efficacy.' 'Each vaccine will work openly on a certain percentage of the population.'
Students who have received admission to foreign universities are struggling with unexpected delays, additional living costs and scarcity of vaccine supplies.
However, in two different dose regimens, the vaccine's efficacy was 90 per cent in one and 62 per cent in the other.
Over time, as more mutations occur, the vaccine may need to be altered.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
After healthcare and frontline workers, priority will be given to those above 50 years of age and the under-50 population groups with co-morbidities numbering around 27 crore, it added.
'We lost our place in being first in the epidemic, when it hit India so hard, but we were actually the epicentre of the epidemic from essentially April 2020, for almost an entire year. We had such high cases. We were the country that had the most mixed response.'
Sun Pharmaceutical Industries on Friday said that it has received the US Food and Drug Administration's nod to market a generic version of alprazolam, an anti-anxiety drug, in the US market.
Scientists around the world, including in India, suggest it hasn't been tested properly given the time constraint and there may not be enough evidence to prove its efficacy.
Fixed-dose combinations are medicines that come mixed in a certain proportion.
US-based Eli Lilly has planned to continue its focus on innovation-driven products, instead of opening up to opportunities in off-patent generic drugs, being tapped by its larger competitors like GSK and Pfizer.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.
At least a dozen global firms, including Roche, Pfizer and Astra Zeneca got a nod from the Drugs Controller General of India to conduct over 50 clinical trials on Indian volunteers this month, official data reveals. The global clinical research outsourcing market is projected to touch $23 billion by 2011, with consultancy firm KPMG estimating that India will corner 15 per cent of this in two years.
The Clinical Research sector is emerging as an attractive option for science graduates, doctors, management/ IT professionals, alike.
Speaking in favour of the US forging collaborations with Indian firms and academic institutes in the field of biopharma and healthcare sector, Pfizer President (Global R&D) Martin Mackay said not only there is a great willingness to collaborate in India, there is a great ability of Indian companies to adapt to western needs. India can be a major centre for innovation globally said Joe Smith, vice-president at Johnson & Johnson.
